Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.

Autor: van der Aart-van der Beek AB; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy, Martini Hospital, Groningen, The Netherlands., Apperloo E; Department of Internal Medicine, Isala Hospital, Zwolle, The Netherlands., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands., Rouw DB; Department of Radiology, Martini Hospital, Groningen, The Netherlands., Sjöström CD; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Friedli I; Antaros Medical AB, BioVenture Hub, Mölndal, Sweden., Johansson L; Antaros Medical AB, BioVenture Hub, Mölndal, Sweden., van Raalte DH; Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands., Hoogenberg K; Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Jun; Vol. 25 (6), pp. 1758-1768. Date of Electronic Publication: 2023 Mar 13.

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.

Autor: van Ruiten CC; Diabetes Centre, Department of Internal Medicine, Amsterdam UMC, Location VUMC, Amsterdam, The Netherlands., van der Aart-van der Beek AB; Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.; Clinical Pharmacy, Martini Hospital, Groningen, The Netherlands., IJzerman RG; Diabetes Centre, Department of Internal Medicine, Amsterdam UMC, Location VUMC, Amsterdam, The Netherlands., Nieuwdorp M; Diabetes Centre, Department of Internal Medicine, Amsterdam UMC, Location VUMC, Amsterdam, The Netherlands., Hoogenberg K; Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands., van Raalte DH; Diabetes Centre, Department of Internal Medicine, Amsterdam UMC, Location VUMC, Amsterdam, The Netherlands., Heerspink HJL; Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2021 Aug; Vol. 23 (8), pp. 1851-1858. Date of Electronic Publication: 2021 May 14.

Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.

Autor: van der Aart-van der Beek AB; Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands.; Clinical Pharmacy, Martini Hospital, Groningen, The Netherlands., Koomen JV; Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands., Dekkers CCJ; Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands., Barbour SJ; Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Boulton DW; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA., Gansevoort RT; Department of Nephrology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands., Greasley PJ; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Abdul Gafor AH; Department of Medicine, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia., Laverman GD; Department of Internal Medicine, ZGT Hospital, Almelo and Hengelo, The Netherlands., Li Q; The George Institute for Global Health, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia., Lim SK; Division of Nephrology, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Stevens J; Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands., Vervloet MG; Department of Nephrology and Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, Amsterdam, The Netherlands., Singh S; Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada., Cattran DC; Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada., Reich HN; Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada., Cherney DZI; Division of Nephrology, Department of Medicine, University Health Network and University of Toronto, Toronto, ON, Canada., Heerspink HJL; Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands. h.j.lambers.heerspink@umcg.nl.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2021 Apr; Vol. 60 (4), pp. 517-525. Date of Electronic Publication: 2021 Feb 15.

Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine.

Autor: van der Aart-van der Beek AB; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands; Martini Hospital, Department of Clinical Pharmacy, Groningen, Netherlands. Electronic address: a.b.van.der.beek@umcg.nl., Wessels AMA; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands., Heerspink HJL; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands., Touw DJ; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands; University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmaceutical Analysis, Groningen, Netherlands.

Publikováno v: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2020 Sep 01; Vol. 1152, pp. 122257. Date of Electronic Publication: 2020 Jun 26.

Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice.

Autor: van der Aart-van der Beek AB; Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands., Heerspink HJL; Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands. h.j.lambers.heerspink@umcg.nl.

Publikováno v: Nature reviews. Nephrology [Nat Rev Nephrol] 2020 Aug; Vol. 16 (8), pp. 433-434.